Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Decreases By 98.1%

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the recipient of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 100 shares, a decline of 98.1% from the October 15th total of 5,200 shares. Based on an average daily volume of 13,200 shares, the days-to-cover ratio is currently 0.0 days.

SAB Biotherapeutics Stock Performance

Shares of NASDAQ SABSW remained flat at $0.05 during trading on Thursday. The stock had a trading volume of 11,961 shares, compared to its average volume of 19,536. SAB Biotherapeutics has a 52-week low of $0.01 and a 52-week high of $0.19. The business’s 50-day moving average is $0.04 and its 200-day moving average is $0.04.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.